Previous 10 | Next 10 |
home / stock / bct:cc / bct:cc news
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune checkpoint inhibitor (CPI) Tumor reductions observed in heavily pretreated patient...
In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s combination regimen exceeded that of similar studies* Progression Free Survival (PFS) was similar or better than last regimen in 40% of the patients highlighting clinica...
VersaBank (VBNK:CA) is expected to report $0.44 for Q4 2023 Genesis Land Development Corp. (GDC:CA) is expected to report for Q2 2024 Aberdeen International Inc. (AAB:CA) is expected to report for Q1 2024 Crown Capital Partners Inc. (CRWN:CA) is expected to report for Q1 2024 Diam...
Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for similar patients reported in the literature*). 32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit. ...
BriaCell’s Bria-IMT ™ combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning “Cold” tumors “Hot” on ImmunoPET imaging Advanced protein array technologies showed unique ant...
After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. Significant ocular pain reduction recorded. Heavily treated patient had 7 prior failed regimens ....
BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell’s next generation breast and prostate cancer immunotherapies Data supports further development of BriaCell’s next generation personalized immunotherapy platform with potent ant...
Canadian Critical Minerals Inc. (CCMI:CA) is expected to report for quarter end 2023-08-31 Advantage Energy Ltd. (AAV:CA) is expected to report $0.16 for Q3 2023 Canadian Utilities Limited Class A Non-Voting Shares (CU:CA) is expected to report for Q3 2023 Newmont Corporation (NGT:CA)...
BriaCell Therapeutics Corp. (BCT:CA) is expected to report $-0.52 for Q4 2023
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...
News, Short Squeeze, Breakout and More Instantly...
Briacell Therapeutics Corp. Company Name:
BCT:CC Stock Symbol:
TSXC Market:
Briacell Therapeutics Corp. Website:
A look at the top 10 most actives in Canada Canadian Natural Resources Limited (CNQ) rose 0.2% to $48.92 on volume of 19,781,731 shares iShares S&P/TSX 60 Index ETF (XIU) fell 0.5% to $34.3919 on volume of 13,629,336 shares Constellation Software Inc. Unsecured Subordinated Floating R...
A look at the top 10 most actives in Canada Constellation Software Inc. Unsecured Subordinated Floating Rate Debentures Series 1 (CSU.DB) rose 0.4% to $123 on volume of 12,106,000 shares Royal Bank of Canada (RY) rose 0.4% to $154 on volume of 4,630,267 shares iShares S&P/TSX 60 Index...
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously rep...